Medical Editor: John P. Cunha, DO, FACOEP
Inveltys (loteprednol etabonate ophthalmic suspension) is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. Common side effects of Inveltys include:
These reactions may be a consequence of the surgical procedure.
The dose of Inveltys is one to two drops of instilled into the affected eye twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period. Inveltys may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Inveltys. Inveltys is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to the drug. Inveltys is not absorbed systemically by the mother following topical ophthalmic administration, and breastfeeding is not expected to result in exposure of the child to Inveltys. Consult your doctor before breastfeeding.
Our Inveltys (loteprednol etabonate ophthalmic suspension) 1%, for Topical Ophthalmic Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The most common adverse drug reactions in the clinical trials with INVELTYS were eye pain and posterior capsular opacification, both reported in 1% of patients. These reactions may have been the consequence of the surgical procedure.
Read the entire FDA prescribing information for Inveltys (Loteprednol Etabonate Suspension)